|Bid||0.7980 x 800|
|Ask||0.8070 x 1200|
|Day's range||0.7500 - 0.8490|
|52-week range||0.3700 - 13.2200|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||15 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||0.43|
Sundial Announces Results of its Annual General and Special Meeting of Shareholders and Details of the Share Consolidation
This morning, Sundial issued a press release announcing our financial results for the first quarter ended March 31, 2020. Presenting on this morning's call, we have Zach George, chief executive officer; Jim Keough, chief financial officer; and Andrew Stordeur, president and chief operating officer.
As consideration for the Bridge Farm Disposition, the Purchaser will (i) assume $45 million of debt under Sundial's existing $115 million term debt facility (the "Term Debt Facility"), (ii) assume the contingent consideration liabilities related to the remaining earn-out and additional share obligations under the original Bridge Farm acquisition agreement, dated as of July 2, 2019 , and (iii) cancel approximately 2,700,000 of Sundial common shares currently held by certain members of the Purchaser. Sundial will not receive any cash consideration in connection with the transaction.
As previously announced, the Company received waivers and agreements related to defaults under its existing credit agreements on March 30, 2020 subject to completion of certain defined milestones by April 15, 2020 . In addition, the Company is in advanced stages of discussions for the potential sale of its Bridge Farm assets and restructuring of the related credit facility.
LETHBRIDGE, AB , May 5, 2020 /CNW/ - Pathway RX Inc. ("Pathway Rx"), a research company dedicated to developing custom cannabis therapies to treat specific diseases and Swysh Inc. ("Swysh"), a cannabinoid oral health product developer, today announced that they intend to further advance their research to evaluate the potential for medical cannabis to treat COVID-19 and its possible complications. Results from a study by Pathway Rx were recently shared publicly and the research paper was submitted to a scientific journal for peer-review.
"We have taken significant actions to restructure our business over the last few months to drive operational efficiencies and adapt to current market conditions," said Zach George , Sundial's Chief Executive Officer. On January 30 th, Sundial announced an annualized cost reduction target of $10 -15 million.
Sundial Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Operational and Financial Outlook
Sundial Growers to Reschedule Fourth Quarter and Fiscal Full-Year 2019 Financial Results to March 30, 2020
Sundial Growers to Reschedule Fourth Quarter and Fiscal Full-Year 2019 Financial Results to March 27, 2020
Sundial Growers to Announce Fourth Quarter and Fiscal Full-Year 2019 Financial Results on March 12, 2020
Sundial and Vir Pharmaceuticals Sign Medical Cannabis Supply Agreement for Australian Chronic Pain Clinical Studies
Navigating the process to access medical cannabis can be confusing to patients, and this content rich e-commerce platform aims to streamline the process. In delivering an elevated medical Cannabis experience to Canadians, Sundial will also leverage its research capabilities created by the 50% acquisition of Pathway Rx Inc. (PathwayRx). PathwayRx will implement learnings from its research to develop unique medical cannabis products targeted for use with specific medical conditions.
CALGARY , Dec. 12, 2019 /CNW/ - More than one-third of Canadian consumers are willing to spend more money for quality products, according to the latest BDS Analytics Consumer Insights Survey (Q1 2019). Created by and for cannabis enthusiasts and connoisseurs, consumers will not only be able to enjoy the highest quality cannabis in traditional flower and pre-roll formats, but in new vape formats as well.
CALGARY , Nov. 28, 2019 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial") and Greg Mills , Chair of the Board, are pleased to announce that Zachary George has been appointed to the Board of Directors ("Board"), effective November 27, 2019 . Mr. George will also be the Chair of the newly formed Operations and Capital Committee of the Board. "We are excited to welcome Zach as a new director to Sundial's Board," said Ted Hellard , Executive Chairman of Sundial.
NEW YORK, Nov. 25, 2019 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sundial Growers Inc. (NASDAQ: SNDL) pursuant and/or.
NEW ORLEANS, Nov. 24, 2019 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they.
SAN FRANCISCO, Nov. 24, 2019 -- Hagens Berman urges Sundial Growers Inc. (NASDAQ: SNDL) investors who have suffered losses in excess of $50,000 to submit their losses now or.
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Sundial Growers Inc. (“Sundial” or the “Company”) (NASDAQ: SNDL) and certain of its officers, on behalf of shareholders who purchased Sundial securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Sundial’s August 1, 2019 initial public stock offering (the “IPO” or the “Offering”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Federal Securities Laws of 1933.